SOPH
NASDAQSOPHiA GENETICS SA
Price$5.25+0.07 (+1.35%)
01:30 PM07:45 PM
News · 26 weeks120-33%
2025-12-142026-06-07
Mix10290d
- Insider88(86%)
- SEC Filings9(9%)
- Other3(3%)
- Earnings2(2%)
Latest news
25 items- INSIDERChief Financial Officer Cardoza George bought $99,000 worth of Ordinary Shares (20,000 units at $4.95), increasing direct ownership by 7% to 311,458 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 6-K filed by SOPHiA GENETICS SA6-K - SOPHiA GENETICS SA (0001840706) (Filer)
- PRSOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer CenterSOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision OncologyNEW YORK, June 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA GENETICS's Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world.
- INSIDERChief Medical Officer Menu Philippe sold $24,774 worth of Ordinary Shares (5,000 units at $4.95) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 250,780 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERPresident Muken Ross sold $3,501 worth of Ordinary Shares (761 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.11% to 680,911 units (SEC Form 4) (tax liability)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $2,798 worth of Ordinary Shares (608 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.10% to 626,280 units (SEC Form 4) to satisfy tax liability4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Executive Officer Camblong Jurgi sold $20,658 worth of Ordinary Shares (4,486 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.12% to 3,629,495 units (SEC Form 4) (withholding tax)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Medical Officer Menu Philippe sold $2,800 worth of Ordinary Shares (608 units at $4.61) as part of a pre-agreed trading plan, decreasing direct ownership by 0.24% to 255,780 units (SEC Form 4) (tax withholding)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Legal Officer Van Well Daan sold $3,149 worth of Ordinary Shares (684 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.20% to 345,052 units (SEC Form 4) to satisfy tax liability4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief People Officer Valente Manuela sold $1,747 worth of Ordinary Shares (380 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 214,691 units (SEC Form 4) (tax withholding)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Sales Officer Puylaert Kevin sold $150 worth of Ordinary Shares (33 units at $4.54), decreasing direct ownership by 0.02% to 148,164 units (SEC Form 4) to satisfy withholding tax4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 6-K filed by SOPHiA GENETICS SA6-K - SOPHiA GENETICS SA (0001840706) (Filer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $18,168 worth of Ordinary Shares (4,000 units at $4.54) as part of a pre-agreed trading plan, decreasing direct ownership by 0.63% to 626,888 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Medical Officer Menu Philippe sold $23,344 worth of Ordinary Shares (5,000 units at $4.67) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 256,388 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERDirector Hibbs Kathy L sold $35,037 worth of Ordinary Shares (7,508 units at $4.67) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 89,768 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- PRSynnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.LONDON, May 13, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's 'revolutionary blood test-first' program. Synnovis, a major provider for England's South East Genomic Medicine Service, worked with SOPHiA GENETICS to launch the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™. This innovative test, originally developed by Memorial Slo
- INSIDERChief Executive Officer Camblong Jurgi sold $43,241 worth of Ordinary Shares (8,500 units at $5.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.23% to 3,633,981 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 6-K filed by SOPHiA GENETICS SA6-K - SOPHiA GENETICS SA (0001840706) (Filer)
- PRSOPHiA GENETICS Reports First Quarter 2026 ResultsBOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 68.0% on a reported basis and 75.4% on an adjusted basis, compared to 68.7% reported and 75.7% adjusted in the prior year periodIFRS net loss was $19.3 million, an increase of 11% year-over-year; Adjusted EBITDA loss was $9.2 million, improving 3% year-over-year"We st
- SECSEC Form 6-K filed by SOPHiA GENETICS SA6-K - SOPHiA GENETICS SA (0001840706) (Filer)
- INSIDERChief Medical Officer Menu Philippe sold $24,089 worth of Ordinary Shares (5,000 units at $4.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 261,388 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Van Well Daan4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Xu Zhenyu4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Valente Manuela4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Menu Philippe4 - SOPHiA GENETICS SA (0001840706) (Issuer)
SOPH FAQ
7 questionsWhat does SOPHiA GENETICS SA do?
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.Where does SOPH stock trade?
SOPHiA GENETICS SA (SOPH) is listed on NASDAQ.What sector and industry is SOPH in?
SOPHiA GENETICS SA operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did SOPHiA GENETICS SA go public?
SOPHiA GENETICS SA (SOPH) completed its IPO in 2021.What are analysts saying about SOPH?
SOPHiA GENETICS SA has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $1100.00 price target on 2024-12-18.What companies are similar to SOPH?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SOPH side-by-side with any of them on Quantisnow.How can I track SOPH on Quantisnow?
Quantisnow aggregates SOPHiA GENETICS SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SOPH to receive live email and push alerts on every new disclosure.